Approximately 150 consultants and specialists in oncology in the Kingdom launched the latest biological immunological development to combat high-risk "lethal" breast cancer after the American health observers and the European Commission approved their approval of the recommendations of the Medicines Agency, proving giving new hope to the drug "Birgitta" in preventing the growth of cells cancer. It is scheduled that this treatment will be implemented soon in more than 30 hospitals and cancer centers in the Kingdom in the regions of Riyadh, the Eastern, Western and Qassim, after 98% of the specialist doctors who met this week in the cities of Jeddah and then Riyadh to launch the medicine "Birgitta" confirmed its contribution to the treatment of breast cancer. The diffuser is of the high-risk type. Dr. Atlal Abu Sanad is a consultant oncologist and clinical researcher in the field of molecular tumors at the University Hospital at King Abdulaziz University in Jeddah, that this development is a promising treatment, which are biologically modified antibodies that target the Gene Hair 2 receptors present in 15-20% of all breast cancers, as it is used with Chemotherapy combined with other biological treatments would help doctors control the development and growth of cancer, which enhances the chances of life for a longer period without significant disease progression in patients with metastatic breast cancer who have a high rate of HER2 gene.